- Home
- CLLS vs ATLN Comparison
CLLS vs ATLN Comparison
Compare CLLS & ATLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- ATLN
- Stock Information
- Founded
- CLLS 1999
- ATLN 2014
- Country
- CLLS France
- ATLN United States
- Employees
- CLLS N/A
- ATLN N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- ATLN
- Sector
- CLLS Health Care
- ATLN
- Exchange
- CLLS Nasdaq
- ATLN NYSE
- Market Cap
- CLLS 144.4M
- ATLN 137.6M
- IPO Year
- CLLS 2007
- ATLN 2021
- Fundamental
- Price
- CLLS $1.53
- ATLN $3.00
- Analyst Decision
- CLLS Buy
- ATLN
- Analyst Count
- CLLS 3
- ATLN 0
- Target Price
- CLLS $7.00
- ATLN N/A
- AVG Volume (30 Days)
- CLLS 84.6K
- ATLN 35.2K
- Earning Date
- CLLS 05-27-2025
- ATLN 01-01-0001
- Dividend Yield
- CLLS N/A
- ATLN N/A
- EPS Growth
- CLLS N/A
- ATLN N/A
- EPS
- CLLS N/A
- ATLN N/A
- Revenue
- CLLS $49,217,000.00
- ATLN $442,609,814.00
- Revenue This Year
- CLLS $48.52
- ATLN N/A
- Revenue Next Year
- CLLS $5.17
- ATLN N/A
- P/E Ratio
- CLLS N/A
- ATLN N/A
- Revenue Growth
- CLLS 435.38
- ATLN 10.27
- 52 Week Low
- CLLS $1.10
- ATLN $1.65
- 52 Week High
- CLLS $3.32
- ATLN $8.98
- Technical
- Relative Strength Index (RSI)
- CLLS 56.17
- ATLN N/A
- Support Level
- CLLS $1.54
- ATLN N/A
- Resistance Level
- CLLS $1.65
- ATLN N/A
- Average True Range (ATR)
- CLLS 0.08
- ATLN 0.00
- MACD
- CLLS -0.00
- ATLN 0.00
- Stochastic Oscillator
- CLLS 58.62
- ATLN 0.00
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.